AI continues to change the landscape of retinal disease management regarding diagnosis, monitoring and treatment, and an AI software from India may elevate the field even further.
According to a press release, Remidio, headquartered in Bengaluru, India, and focused on vision health, is harnessing AI to offer widespread cost-effective diabetic retinopathy (DR) screening without the need for internet access. Medios DR AI has been approved by the Central Drugs Standard Control Organisation in India and previously received a CE mark in Europe and approval from the Health Sciences Authority in